Top Cannabis Stocks to Watch as Europe's CBD Market Grows 400% - Seite 3

HEXO Corporation (NYSE:HEXO)(TSX:HEXO) has received a medical cannabis installation license. The license, issued by the Greek government, will allow HEXO MED to establish cultivation, processing and manufacturing facilities in the region of Thessaly, Greece. With HEXO Corp's experience in the industry, HEXO MED is poised to become a leader in the European cannabis landscape. "This is a major step for HEXO as we continue to execute towards becoming a top three global cannabis company," said Sebastien St-Louis, HEXO Corp CEO and co-founder. "Receiving licensing in Greece will allow us to bring know-how and brands powered by HEXO to the European market. The new facility will also drive value for current and future Fortune 500 partners by giving them access to licensed infrastructure internationally with the vision of capturing first-mover advantage in the burgeoning European cannabis market." 

ICC International Cannabis Corp. (CSE:WRLD-U)(OTCPK:WLDCF) has completed a Technical Feasibility Study relating to its proposed 150,000 square foot Danish GACP/EU-GMP certified Greenfield cultivation, processing and manufacturing facility. The Company previously engaged a leading Denmark based international pharma engineering firm to perform a comprehensive Feasibility Study for its planned Danish Facility; situated on a 100-acre land parcel in Møldrup, Denmark. The initiation of the Danish Facility project marks another milestone for ICC, as it continues to execute on its long-term economically sustainable and alpha generating corporate stratagem. Leveraging proprietary design and build IP, as well as its proven cultivation methodologies, ICC seeks to achieve full optimization of each square foot in the Danish Facility. The Company forecasts that further engineering efficiencies will be achieved by way of customized process design and building systems. Initial conclusions of the Feasibility Study indicate that once fully operational, ICC's Danish Facility will achieve annualized production capabilities of circa 20,000,000 grams of artisanal grown, ultra-premium dried cannabis flower for sale into high value medical markets.